New USPSTF Recommendations on Breast Cancer Chemoprophylaxis

Background and Objective

Tamoxifen, raloxifene, and aromatase inhibitors reduce risk for invasive estrogen-receptor–positive breast cancer by about 50% in high-risk menopausal women; however, the ability of current risk assessment tools to distinguish between women who will and will not develop cancer is modest.

Key Recommendations

• Clinicians should discuss risk-reducing medications with women at excess risk for breast cancer and low risk for adverse effects of these medications. This applies to women aged ≥35 (including those with biopsy-identified atypical ductal or lobular hyperplasia or lobular carcinoma in situ), but not women with a prior history of invasive breast canc…